Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0257 • ACR Convergence 2020
Application of Text Mining Methods to Identify Lupus Nephritis from Electronic Health Records
Milena Gianfrancesco¹, Suzanne Tamang², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹University of California, San Francisco, San Francisco, CA, ²Stanford Center for Population Health Sciences, Redwood City, CA, ³University of California, San Francisco, Atherton, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is a frequent complication of SLE and associated with higher morbidity and mortality. Accurate estimates of the prevalence of LN in…
Abstract Number: 0274 • ACR Convergence 2020
The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades
Mehmet Hocaoglu¹, Shirley-Ann Osei-Onomah², Jesse Dabit³, Rachel Giblon³, Thomas O'Byrne³, Fernando C. Fervenza³, Cynthia Crowson⁴ and Ali Duarte-Garcia³, ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Estimating the incidence of lupus nephritis (LN) is important to understand disease burden, particularly since patients with LN have a higher morbidity and mortality…
Abstract Number: 0292 • ACR Convergence 2020
Exhausted pSTAT5-IFNα Signaling Pathways in SLE Patients Are Correlated with Age-associated B Cells and Disease Activity
Samantha Slight-Webb¹, Miles Smith², Kevin Thomas¹, Susan Macwana¹, Holden Maecker³, Paul Utz⁴, Judith James⁵ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by periods of elevated and suppressed clinical symptoms. Specific cell subsets, such as CD11c+ age-associated…
Abstract Number: 0436 • ACR Convergence 2020
The Addressing Lupus Pillars for Health Advancement (ALPHA) Project: Establishing Consensus and Prioritization of Global Community Recommendations to Address Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Karin Tse¹, Sanjyot Sangodkar², Kathleen Arntsen³, Sang-Cheol Bae⁴, Lauren Bloch², Ian Bruce⁵, Erin Connolly-Strong⁶, Karen Costenbader⁷, Thomas Dörner⁸, Sydney Evans⁹, Timothy Franson², Kenneth Getz¹⁰, Amy Kao¹¹, Kenneth Kalunian¹², Bradley Dickerson¹³, Susan Manzi¹⁴, Eric Morand¹⁵, Yaritza Peña¹⁰, Sandra Raymond¹⁶, Brad Rovin¹⁷, Laura Schanberg¹⁸, Joan Von Feldt¹⁹, Victoria Werth²⁰, Angel Williams²¹, David Zook² and Leslie Hanrahan¹⁶, ¹Lupus Foundation of America, DC, WA, ²Faegre Drinker Consulting, Washington, DC, ³Lupus and Allied Diseases Association, Inc., Verona, NY, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Mallinckrodt, Austin, TX, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸DRFZ and Charité University Hospitals, Berlin, Germany, ⁹Lupus Patient Representative, Riverdale, MD, ¹⁰Tufts Center for the Study of Drug Development, Boston, MA, ¹¹EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ¹²University of California San Diego, La Jolla, CA, ¹³Aurinia Pharmaceuticals, Fort Washington, PA, ¹⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ¹⁵Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ¹⁶Lupus Foundation of America, Washington, DC, ¹⁷The Ohio State University, Columbus, ¹⁸Duke University Medical Center, Durham, NC, ¹⁹GlaxoSmithKline, WILMINGTON, DE, ²⁰University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²¹Lupus Patient Representative, Richmond, VA
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus effort to identify, prioritize and address top barriers in lupus impacting…
Abstract Number: 0574 • ACR Convergence 2020
Is Hydroxychloroquine Use a Proxy for Health Care Access? Predictors of First Dispensing Among Medicaid Beneficiaries with Incident Lupus
Katherine Pryor¹, Chang Xu¹, Jamie Collins¹, Karen Costenbader² and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine/chloroquine (HCQ/CQ) is considered to be the backbone of systemic lupus erythematosus (SLE) care. Differences in receipt of HCQ/CQ may exacerbate disparities in adverse…
Abstract Number: 0840 • ACR Convergence 2020
Amelioration of Immune Complex-Mediated Glomerulonephritis via CD6 Modulation
Samantha Chalmers¹, Sayra Garcia¹, Leal Herlitz², Jeanette Ampudia³, Cherie Ng⁴, Stephen Connelly³ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Cleveland Clinic, Cleveland, OH, ³Equillium, Inc, San Diego, CA, ⁴Equillium, Inc, La Jolla, CA
Background/Purpose: CD6 is a co-stimulatory receptor, predominantly expressed on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen-presenting…
Abstract Number: 0858 • ACR Convergence 2020
Leflunomide: A Safe and Effective Alternative in Systemic Lupus Erythematosus
Irene Carrión-Barberà¹, Tarek Carlos Salman Monte¹, Luciano Polino¹, Miguel Mejía¹, Manel Ciria¹, Carolina Pérez-García¹, Eva Rodríguez¹ and Jordi Monfort¹, ¹Hospital del Mar, Barcelona, Spain
Background/Purpose: Leflunomide (LEF) is a DMARD commonly used safely and effectively in rheumatoid arthritis. The experience with LEF in SLE is mainly based on what…
Abstract Number: 0946 • ACR Convergence 2020
ENPP1 Regulates UV Light Triggered Type I Interferon Response in the Skin
Sladjana Skopelja-Gardner¹, Joyce Tai², Xizhang Sun² and Keith Elkon², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle
Background/Purpose: Systemic lupus erythematosus (SLE) patients have a prominent type I interferon (IFN-I) signature in both the lesional and non-lesional skin. We recently showed that…
Abstract Number: 1018 • ACR Convergence 2020
Seasonal Variation in the Treat-to-Target Rate of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE): A Cohort Study on Self-reported Data from Smart System of Disease Management (SSDM)
Lijun Wu¹, Zhanyun Da², Hongzhi Wang³, Jianlin Huang⁴, Bin Wu⁵, Henglian Wu⁶, Fang He⁷, Fen Wang⁸, Rong Du⁹, Linchong Su¹⁰, Qiaoqiao Yao¹¹, Rui Wu¹², Zhenbin Li¹³, Xiaohan Wang¹⁴, Yuhong Liu⁹, Chuanjing Li¹⁵, Xiaomei Lei¹⁶, Minjun Wang¹⁷, Hui Xiao¹⁷, Yuhua Jia¹⁸, Yihong Liu¹⁷, Xin Chen¹⁷, Shengsong Jia¹⁷, Bing Wu¹⁸, Yuan Liu¹⁷, Fei Xiao¹⁸ and Lingli Dong¹⁹, ¹People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China (People's Republic), ²The affiliated Hospital of Nantong University, Nantong, Jiangsu, China (People's Republic), ³The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ⁴The sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ⁵Chongqing Hospital of Traditional Chinese Medicine, chongqing, Chongqing, China (People's Republic), ⁶Dongguan Donghua Hospital, Dongguan, Guangdong, China (People's Republic), ⁷Suining Central Hospital, Suining, Sichuan, China (People's Republic), ⁸The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (People's Republic), ⁹Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), ¹⁰Minda Hospital of Hubei Minzu University, Enshi, Hubei, China (People's Republic), ¹¹China Resources Wuhan Iron and Steel General Hospital, Wuhan, Hubei, China (People's Republic), ¹²The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹³Chinese people ’s liberation army joint service support force 980 hospital, shijiazhuang, Jiangxi, China (People's Republic), ¹⁴Anyang district hospital, Anyang, Henan, China (People's Republic), ¹⁵Xiaogan Central Hospital of Hubei Province, Xiaogan, Hubei, China (People's Republic), ¹⁶Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), ¹⁷Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁸Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁹Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic)
Background/Purpose: Treat-to-Target(T2T) is the main therapeutic strategy for patients with RA and SLE. There has been no report on comparation of seasonal variations on T2T…
Abstract Number: 1147 • ACR Convergence 2020
Development of a Digital Toolkit to Improve Quality of Life of Patients with Systemic Lupus Erythematosus: A Pilot Study
Jerik Leung¹, Ashish Shrestha¹, Jennifer Ra², Laura Brennan³, Alfred Kim⁴ and Elizabeth Baker¹, ¹Saint Louis University, College for Public Health and Social Justice, St. Louis, ²Washington University School of Medicine, Lake Forest, CA, ³Transtria, St. Louis, ⁴Washington University School of Medicine, St. Louis, MO
Background/Purpose: Individuals living with systemic lupus erythematosus (SLE) face a number of challenges in managing their condition. Initial interviews and community forums with SLE patients…
Abstract Number: 1273 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on the Fibromyalgia Symptoms of SLE Patients
Rebecca Sadun¹, Jennifer Rogers², Kai Sun¹, Karissa Grier¹, Lisa Criscione-Schreiber³, Mithu Maheswaranathan¹, Jayanth Doss¹ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke, Durham, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Many patients with SLE experience symptoms of chronic pain and fatigue, often meeting criteria for fibromyalgia (FM). In this study, we sought to examine…
Abstract Number: 1289 • ACR Convergence 2020
Sex Differences in Mental Health and Quality of Life and Their Impact in the Treatment of Patients with Systemic Lupus Erythematosus
Lilian Cano-Cruz¹, Eduardo Aguirre-Aguilar¹, Martín Valdez-López², Ana Barrera-Vargas¹, Virginia Pascual Ramos¹ and Javier Merayo-Chalico³, ¹INSTITUTO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION SALVADOR ZUBIRAN, Mexico City, Distrito Federal, Mexico, ²INSTITUTO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION SALVADOR ZUBIRAN, Mexico City, Mexico, ³INSTITUTO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION SALVADOR ZUBIRAN, Ciudad de Mexico, Distrito Federal, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects young women. It is usually more aggressive in men and carries a worse prognosis. Information about gender differences…
Abstract Number: 1451 • ACR Convergence 2020
Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE
Michelle Petri¹, Laurence Magder² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Although anti-beta2 glycoprotein is one of the three antiphospholipid antibodies recognized in the Sydney APS classification criteria, it is one of the least studied. …
Abstract Number: 1516 • ACR Convergence 2020
The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership
Philip Carlucci¹, Kristina Deonaraine¹, Andrea Fava², Jessica Li³, David Wofsy⁴, Judith James⁵, Chaim Putterman⁶, Betty Diamond⁷, Derek Fine⁸, Jose Monroy-Trujillo⁸, Kristin Haag⁸, William Apruzzese⁹, H. Michael Belmont¹⁰, Peter Izmirly¹¹, Sean Connery¹², Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Partnership in SLE Network¹⁹, Michelle Petri²⁰ and Jill Buyon²¹, ¹New York University School of Medicine, New York, ²Johns Hopkins, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Northwell Health, Hartford, ⁸Johns Hopkins University, Baltimore, ⁹., Boston, ¹⁰NYU School of Medicine, New York, NY, ¹¹Department of Medicine, New York University School of Medicine, New York, NY, ¹²Texas Tech University Health Sciences Center, Lubbock, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶University of California San Francisco, San Francisco, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸School of Health Sciences, University of California, La Jolla, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with…
Abstract Number: 1674 • ACR Convergence 2020
Pediatric and Adolescent One Year Protocol Kidney Biopsies Should Be Performed, Even in Patients with Complete Remission of Their Lupus Nephritis
Peter Yorgin¹, Suhas Radhakrishna¹, Caitlin Carter¹, Johanna Chang¹, Katayoon Shayan¹, Lieuko Nguyen¹, Peter Chiraseveenuprapund¹ and Robert Sheets², ¹UCSD/Rady Children's Hospital, San Diego, CA, ²University of California San Diego, San Diego, CA
Background/Purpose: The value of one-year protocol kidney biopsies in children who have proliferative lupus nephritis (LN) is unclear, particularly in patients who meet CARRA criteria…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].